Osaic Holdings
NTLA icon

Osaic Holdings’s Intellia Therapeutics NTLA Stock Holding History

Osaic Holdings’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
63,242
+43,257
+216% +$605K ﹤0.01% 2939
2026
Q1 		$256K Sell
19,985
-3,137
-14% -$40K ﹤0.01% 3942
2025
Q4 		$208K Buy
23,122
+2,755
+14% +$37.9K ﹤0.01% 4130
2025
Q3 		$314K Buy
20,367
+303
+2% +$3.73K ﹤0.01% 3829
2025
Q2 		$188K Buy
20,064
+2,373
+13% +$19.5K ﹤0.01% 3995
2025
Q1 		$126K Buy
17,691
+10,697
+153% +$108K ﹤0.01% 4006
2024
Q4 		$81.4K Sell
6,994
-28,361
-80% -$443K ﹤0.01% 4345
2024
Q3 		$727K Sell
35,355
-1,774
-5% -$40.9K ﹤0.01% 2533
2024
Q2 		$831K Sell
37,129
-30
-0.1% -$714 ﹤0.01% 2339
2024
Q1 		$1.02M Buy
37,159
+1,278
+4% +$35.5K ﹤0.01% 2303
2023
Q4 		$1.09M Buy
35,881
+11,878
+49% +$341K ﹤0.01% 2431
2023
Q3 		$759K Buy
24,003
+3,978
+20% +$154K ﹤0.01% 2882
2023
Q2 		$818K Sell
20,025
-1,323
-6% -$53.6K ﹤0.01% 2697
2023
Q1 		$794K Buy
21,348
+1,034
+5% +$40.6K ﹤0.01% 2694
2022
Q4 		$709K Buy
20,314
+12,722
+168% +$605K ﹤0.01% 2710
2022
Q3 		$423K Buy
7,592
+15
+0.2% +$931 ﹤0.01% 3046
2022
Q2 		$391K Sell
7,577
-1,068
-12% -$54.2K ﹤0.01% 3172
2022
Q1 		$826K Buy
8,645
+88
+1% +$7.46K ﹤0.01% 2748
2021
Q4 		$1.01M Buy
8,557
+360
+4% +$45.1K ﹤0.01% 2392
2021
Q3 		$1.1M Sell
8,197
-2,389
-23% -$362K ﹤0.01% 2256
2021
Q2 		$1.72M Sell
10,586
-1,311
-11% -$102K ﹤0.01% 1852
2021
Q1 		$954K Buy
11,897
+810
+7% +$54.4K ﹤0.01% 2269
2020
Q4 		$602K Buy
11,087
+1,466
+15% +$53.2K ﹤0.01% 2475
2020
Q3 		$191K Sell
9,621
-291
-3% -$6.07K ﹤0.01% 3292
2020
Q2 		$208K Sell
9,912
-3,627
-27% -$61.6K ﹤0.01% 3102
2020
Q1 		$168K Buy
+13,539
New +$182K ﹤0.01% 3034

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Osaic Holdings's NTLA Position: Q2 2026 in Review

Osaic Holdings increased its Intellia Therapeutics (NTLA) stake by 216% in Q2 2026, buying an estimated $605K and bringing the position to 63,242 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2939.

Osaic Holdings first reported a position in NTLA in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.72M in Q2 2021. 328 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Osaic Holdings held 63,242 shares of Intellia Therapeutics worth $1.07M as of Q2 2026.
  • Osaic Holdings bought 43,257 Intellia Therapeutics shares in Q2 2026, an estimated $605K.
  • Intellia Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q2 2026, its #2939 holding.
  • Osaic Holdings first reported a position in Intellia Therapeutics in Q1 2020 and has held it in 26 quarters since.
  • Osaic Holdings's Intellia Therapeutics position peaked at $1.72M in Q2 2021.
  • 328 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Osaic Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.